| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4850253
Max Phase: Preclinical
Molecular Formula: C36H43ClF2N5O3+
Molecular Weight: 667.22
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CC[N+]1(CCCCCCCOc2ccc(-n3cc(C(=O)Nc4cc(F)cc(F)c4)c(=O)c4ccc(N(C)C)nc43)c(Cl)c2)CCCC1
Standard InChI: InChI=1S/C36H42ClF2N5O3/c1-4-44(17-9-10-18-44)16-8-6-5-7-11-19-47-28-12-14-32(31(37)23-28)43-24-30(36(46)40-27-21-25(38)20-26(39)22-27)34(45)29-13-15-33(42(2)3)41-35(29)43/h12-15,20-24H,4-11,16-19H2,1-3H3/p+1
Standard InChI Key: QWZOFZIOKAOORV-UHFFFAOYSA-O
Associated Targets(Human)
COL1A1 promoter (117 Activities)
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 667.22 | Molecular Weight (Monoisotopic): 666.3017 | AlogP: 7.60 | #Rotatable Bonds: 14 |
| Polar Surface Area: 76.46 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
| #RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 12.56 | CX Basic pKa: 2.98 | CX LogP: 3.85 | CX LogD: 3.85 |
| Aromatic Rings: 4 | Heavy Atoms: 47 | QED Weighted: 0.11 | Np Likeness Score: -1.17 |
References
| 1. Lu ZN, Shan Q, Hu SJ, Zhao Y, Zhang GN, Zhu M, Yu DK, Wang JX, He HW.. (2021) Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways., 49 [PMID:34610571] [10.1016/j.bmc.2021.116438] |
Source
Source(1):